Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients
Authors
Keywords
Schizophrenia, <em class=EmphasisTypeItalic >MMP9</em>, <em class=EmphasisTypeItalic >TIMP1</em>, Real time PCR, Expression analysis
Journal
METABOLIC BRAIN DISEASE
Volume 32, Issue 5, Pages 1537-1542
Publisher
Springer Nature
Online
2017-06-04
DOI
10.1007/s11011-017-0043-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glutamate receptor, metabotropic 7 (GRM7) gene variations and susceptibility to autism: A case-control study
- (2016) Rezvan Noroozi et al. Autism Research
- Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders
- (2016) Chiyo Shibasaki et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Schizophrenia genetics complements its mechanistic understanding
- (2016) Elizabeth K Ruzzo et al. NATURE NEUROSCIENCE
- Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia: Table 1.
- (2015) Katarzyna Lepeta et al. SCHIZOPHRENIA BULLETIN
- MATRIX METALLOPROTEINASE-9 (MMP-9) AND ITS TISSUE INHIBITOR-1 (TIMP-1) AS BIOMARKERS OF ALZHEIMER'S DISEASE
- (2014) Barbara Mroczko et al. Alzheimers & Dementia
- The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
- (2014) Wei Hu et al. Annals of the New York Academy of Sciences
- Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine
- (2013) Hidenaga Yamamori et al. NEUROSCIENCE LETTERS
- A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia
- (2013) Tomihisa Niitsu et al. PSYCHIATRY RESEARCH
- Definition and description of schizophrenia in the DSM-5
- (2013) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood–spinal cord barrier after spinal cord injury
- (2012) Jee Y. Lee et al. BRAIN
- Synaptic circuit remodelling by matrix metalloproteinases in health and disease
- (2012) George W. Huntley NATURE REVIEWS NEUROSCIENCE
- Glutamate signaling in the pathophysiology and therapy of schizophrenia
- (2011) Chieh-Hsin Lin et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Schizophrenia Genetics: Where Next?
- (2011) Y. Kim et al. SCHIZOPHRENIA BULLETIN
- Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology?
- (2010) S. Rivera et al. JOURNAL OF NEUROSCIENCE
- Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections
- (2010) Enrico Domenici et al. PLoS One
- Important role of matrix metalloproteinase 9 in epileptogenesis
- (2008) Grzegorz M. Wilczynski et al. JOURNAL OF CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started